Navigation Links
Lexicon to Report First Quarter Financial Results on May 10, 2013
Date:5/3/2013

THE WOODLANDS, Texas, May 3, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, will release its first quarter 2013 financial results on Friday, May 10, 2013 before the financial markets open.  Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the first quarter at 11:00 a.m. Eastern Time on May 10, 2013.

The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international).  The conference ID for all callers is 64449185.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on the website through June 10, 2013.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Tillotts Pharma is strengthening ... Berlin office was opened in January 2017 ... portfolio includes Entocort ® for the treatment of ... ulcerative colitis, and VistaPrep ® for bowel preparation ... pharmaceutical company focused on the treatment of gastrointestinal (GI) ...
(Date:2/23/2017)... , February 23, 2017 The ... have legalized cannabis for recreational use in 2016. According to ... cannabis market was worth an estimated $7.2 billion in 2016 ... rate of 17%. While adult recreational sales are projected to ... 2020, with a 25% CAGR. The market may grow faster ...
(Date:2/23/2017)... Feb. 22, 2017 Orthopedic and cardiac ... as aging demographic patterns lead to an increasing ... sports- and exercise-related injuries, chronic back problems, heart ... sales gains. The future of medical implants faces ... following questions and more: - What types ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research ... those in the fight against cancer, has produced a seminal study that asked ... will release top-line findings in a webinar, Defining Compassionate Care Through the Voices ...
(Date:2/23/2017)... ... 2017 , ... CALNOC, the nation’s first and only nursing quality indicators database ... Empowerment, Value and Collaboration – in Seattle, WA on October 23, 2017. , Dr. ... System in Seattle since 2000. In addition to his role at Virginia Mason, Dr. ...
(Date:2/23/2017)... , ... February 23, 2017 , ... HealthPostures, the desk ... an expert sit stand solutions representative to the Minneapolis Home and Garden Show which ... the event that is garnering national attention is the Minneapolis Convention Center. , ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and lobby of a new healthcare contact center in Georgia, PENETRON Specialty Products ... of the nation’s largest healthcare systems recently invested $51 million to purchase and ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... in recent years. The technology is so cutting edge, in fact, the U.S. ... for stem cell procedures. However, successful patient outcomes in certain clinical stem cell ...
Breaking Medicine News(10 mins):